Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) and Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
Analyst Ratings
This is a summary of recent ratings for Spyre Therapeutics and Actinium Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spyre Therapeutics | 1 | 1 | 13 | 2 | 2.94 |
| Actinium Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Spyre Therapeutics currently has a consensus target price of $110.53, indicating a potential upside of 6.43%. Actinium Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 249.65%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Spyre Therapeutics.
Risk and Volatility
Spyre Therapeutics has a beta of 3.24, meaning that its stock price is 224% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.
Insider & Institutional Ownership
80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 0.9% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Spyre Therapeutics and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spyre Therapeutics | N/A | -35.97% | -27.67% |
| Actinium Pharmaceuticals | N/A | -100.85% | -47.89% |
Valuation & Earnings
This table compares Spyre Therapeutics and Actinium Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spyre Therapeutics | $890,000.00 | 11,082.68 | -$155.20 million | ($2.74) | -37.91 |
| Actinium Pharmaceuticals | $35.09 million | 1.28 | -$48.82 million | $0.36 | 3.97 |
Actinium Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Spyre Therapeutics beats Actinium Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
